Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. reports developments for a medical technology company focused on physical rehabilitation and recovery. Its product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, with use in clinical settings and in home or community rehabilitation.
Company news covers financial results, access initiatives for the FDA-cleared ReWalk Personal Exoskeleton, collaborations with rehabilitation providers, and regulatory or clinical disclosures tied to rehabilitation technologies. Other recurring updates address Nasdaq listing compliance, shareholder voting matters, governance changes, material agreements, acquisitions, and capital-structure actions involving ordinary shares and warrants.
Lifeward (NASDAQ: LFWD), a medical technology company, has announced the pricing of a $2.6 million public offering. The offering consists of 4,000,000 ordinary shares with accompanying warrants at a combined price of $0.65 per share and warrant.
The warrants will have an exercise price of $0.65, be immediately exercisable, and expire in five years. If fully exercised, they could generate an additional $2.6 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the proceeds for commercial efforts, working capital, and general corporate purposes, with closing expected around June 26, 2025.
Lifeward (NASDAQ:LFWD) announced a significant legal victory as an Administrative Law Judge (ALJ) ruled that the ReWalk Personal Exoskeleton must be covered by Medicare as a "reasonable and necessary" medical device for individuals with spinal cord injury (SCI). This ruling follows CMS's April 2024 decision establishing a Medicare reimbursement pathway for personal exoskeletons.
The decision reinforces the medical necessity of ReWalk's technology and is expected to influence coverage decisions by commercial insurers. The ReWalk 7, the company's latest innovation and the only personal exoskeleton capable of navigating stairs and curbs, received FDA clearance in March 2025 and is now commercially available in the United States.
Lifeward (NASDAQ: LFWD), a leader in medical technology for people with physical limitations, has announced its participation in the upcoming Sidoti May Virtual Investor Conference. CEO Larry Jasinski and CFO Mike Lawless will represent the company, delivering a corporate presentation on May 21, 2025, at 10:00 AM EDT.
The executives will also host one-on-one meetings with investors during the two-day conference on May 21-22, 2025. Investors can access the presentation through a provided Zoom link and register for both the presentation and one-on-one meetings through the Sidoti website. Registration is complimentary and open to all interested investors, regardless of Sidoti client status.
Lifeward (Nasdaq: LFWD), a global leader in medical technology for people with physical limitations or disabilities, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. CEO Larry Jasinski and CFO Mike Lawless will host a conference call and webcast at 8:30 a.m. EDT to discuss the results.
The earnings call will be accessible via multiple toll-free numbers across the U.S., Germany, and Israel. Investors can also access the webcast through the company's website at GoLifeward.com in the "Investors" section, with an archived version available afterward.
Lifeward announced a significant milestone as the first major U.S. commercial health insurer approves coverage for the ReWalk 7 Personal Exoskeleton. This breakthrough follows the device's U.S. sales launch in April 2025 and its FDA clearance in March 2025.
The ReWalk 7 enables individuals with spinal cord injury (SCI) to stand, walk, and navigate stairs in everyday environments. This approval builds on the 2024 Medicare reimbursement pathway established by CMS, which covers approximately one-third of SCI individuals nationwide.
CEO Larry Jasinski emphasized this development as crucial for market expansion, noting that commercial insurers cover a significant portion of SCI individuals. The company views this approval as momentum for engaging more commercial insurers and strengthening growth prospects.
Lifeward (Nasdaq: LFWD) announced that a paralyzed Israeli soldier has successfully completed training and received a ReWalk Personal Exoskeleton, becoming the first Israeli war casualty to regain walking ability through this technology. The 25-year-old reserve combat soldier from the IDF Paratroopers Reserve Brigade, who suffered paralysis in both legs, underwent rehabilitation at Beilinson Hospital under Dr. Yaron Watts's supervision.
Dr. Watts described this as a 'precedent-setting historic event' and advocated for the system's recognition by the Rehabilitation Department of the Ministry of Defense, similar to smart prosthetics provided to amputees. The Israeli Rehabilitation Department is now evaluating the device's safety and effectiveness for other paralyzed Veterans following this successful case.
Lifeward (NASDAQ: LFWD) has launched the ReWalk 7 Personal Exoskeleton in the U.S. market, following FDA clearance in March 2025. This seventh-generation exoskeleton for individuals with spinal cord injury (SCI) features significant improvements including:
- Customizable walking speeds for indoor/outdoor environments
- Crutch Control system for enhanced user control
- Wrist Control smartwatch and MyReWalk mobile app integration
- Improved battery life and seamless stairs/curbs navigation
- New therapist handheld device for training
The development involved extensive testing with dozens of end users and physical therapists. This launch follows two major milestones: the 2023 addition of stairs and curbs navigation capability to ReWalk 6.0, and the 2024 establishment of a Medicare reimbursement pathway by CMS for personal exoskeletons.